Add to ORKGNivolumab is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) immune checkpoint. It has been approved for its use in several types of advanced solid tumors, including melanoma, lung cancer, and renal cell carcinoma (RCC). The inhibition of PD-1 leads to an enhanced adaptive immune response against tumor cells through the activation of T-cells
Introduction: Treatment with immune checkpoint inhibitors in melanoma patients can cause immune-rela...
Vitiligo is a skin depigmentation disorder resulting from autoimmune destruction of melanocytes. Th...
Nivolumab is a programmed death-1 (PD1) immune checkpoint inhibitor that treats various types of can...
Nivolumab is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) immun...
RATIONALE: The introduction of immune check-point inhibitors (ICIs) in the treatment of solid neopla...
Antibodies directed against programmed death receptor 1 emerged as beneficial immune-checkpoint inhi...
Historically, the median overall survival of patients with metastatic melanoma was less than one yea...
Patients with metastatic renal cell carcinoma (mRCC) have always had a poor prognosis. Recently new ...
Vitiligo-like depigmentation (VLD) is an immune-related adverse event (irAE) of checkpoint-inhibitor...
Introduction:Renal cell carcinomas account for 90% of all malignant neoplasms of the kidney. The mos...
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined ...
Background: Checkpoint inhibitors in melanoma can lead to self-immune side-effects such as vitiligo-...
Nivolumab is a monoclonal antibody, belonging to the checkpoint inhibitors, recently approved for tr...
Programmed death 1 receptor (PD-1) inhibitors, such as nivolumab, are effective in the treatment of ...
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and me...
Introduction: Treatment with immune checkpoint inhibitors in melanoma patients can cause immune-rela...
Vitiligo is a skin depigmentation disorder resulting from autoimmune destruction of melanocytes. Th...
Nivolumab is a programmed death-1 (PD1) immune checkpoint inhibitor that treats various types of can...
Nivolumab is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) immun...
RATIONALE: The introduction of immune check-point inhibitors (ICIs) in the treatment of solid neopla...
Antibodies directed against programmed death receptor 1 emerged as beneficial immune-checkpoint inhi...
Historically, the median overall survival of patients with metastatic melanoma was less than one yea...
Patients with metastatic renal cell carcinoma (mRCC) have always had a poor prognosis. Recently new ...
Vitiligo-like depigmentation (VLD) is an immune-related adverse event (irAE) of checkpoint-inhibitor...
Introduction:Renal cell carcinomas account for 90% of all malignant neoplasms of the kidney. The mos...
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined ...
Background: Checkpoint inhibitors in melanoma can lead to self-immune side-effects such as vitiligo-...
Nivolumab is a monoclonal antibody, belonging to the checkpoint inhibitors, recently approved for tr...
Programmed death 1 receptor (PD-1) inhibitors, such as nivolumab, are effective in the treatment of ...
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and me...
Introduction: Treatment with immune checkpoint inhibitors in melanoma patients can cause immune-rela...
Vitiligo is a skin depigmentation disorder resulting from autoimmune destruction of melanocytes. Th...
Nivolumab is a programmed death-1 (PD1) immune checkpoint inhibitor that treats various types of can...